• Anti-HMGB1 Rabbit Monoclonal Antibody Guide

  2026-08-22

  Anti-HMGB1 Rabbit Monoclonal Antibody MA3057 supports detection of HMGB1 in human, mouse, and rat samples by Western blot, immunohistochemistry, and flow cytometry. It is intended for controlled research workflows only, not diagnostic or therapeutic use, and assay performance should be confirmed in the investigator’s sample matrix.

• Muscle BDNF and Early Neuromuscular Synapse Formation

  2026-08-21

  This study identifies podosome-like structures as spatial control sites for muscle-derived BDNF trafficking and calcium-dependent release during the earliest stages of neuromuscular junction development. By combining live imaging, BDNF loss-of-function, furin inhibition, agrin or nerve stimulation, and muscle-specific knockout mice, the authors connect localized BDNF processing to aneural and synaptic acetylcholine receptor cluster formation.

• Separating Growth Arrest from Cell Death in Cancer

  2026-08-21

  Hannah R. Schwartz’s dissertation identifies a key interpretive problem in in vitro oncology: relative viability and fractional viability are often treated as interchangeable even though they capture different components of drug response. Its framework shows that drugs can influence proliferation and cell death in different proportions and on different timelines, supporting more discriminating experimental design and analysis.

• Caveolin-1, Cholesterol, and MASLD Progression

  2026-08-20

  The reference study identifies caveolin-1 as a regulator of hepatic cholesterol homeostasis that limits endoplasmic reticulum stress and pyroptosis during metabolic dysfunction-associated steatotic liver disease. By integrating a CAV1-deficient mouse model, liver transcriptomics, human samples, and in vitro experiments, the work connects the FXR/NR1H4–ABCG5/ABCG8 axis with disease progression and provides a mechanistic framework for studying cholesterol-driven liver injury.

• BCECF-AM for Plant Autophagy pH Assays

  2026-08-20

  BCECF-AM converts intracellular acid–base changes into a quantitative ratiometric readout, making it a practical complement to genetic and imaging assays of Arabidopsis autophagy. This guide connects vacuolar acidification biology with executable dye-loading, calibration, imaging, and troubleshooting workflows.

• Atrial Natriuretic Peptide: Research Workflows

  2026-08-19

  Build more reproducible ANP experiments for vascular, renal, and adipose models with practical preparation, dosing, controls, and troubleshooting guidance. The workflow also shows how the reference study’s mechanistic design can strengthen cardiovascular disease research without confusing adiponectin findings with ANP biology.

• Neomycin Sulfate: Mechanisms and Research Uses

  2026-08-19

  Neomycin sulfate is an aminoglycoside antibiotic used as a molecular probe for RNA/DNA structure interaction studies and ion-channel mechanisms. Its reported activities include inhibition of hammerhead ribozyme cleavage, disruption of HIV-1 Tat–TAR binding, DNA triplex structure stabilization, and voltage-dependent ryanodine receptor channel block.

• Tomivosertib as a Translational MNK1 Inhibitor

  2026-08-18

  Tomivosertib is a selective MNK1 inhibitor that connects eIF4E phosphorylation with glioblastoma growth, angiogenesis, and chemotherapy response. This article develops an evidence-driven assay framework for distinguishing target engagement, tumor-cell effects, endothelial effects, and treatment sensitization.

• HIV-1 Nuclear Pores License Resting T-Cell Infection

  2026-08-18

  The reference study identifies nuclear pore complex remodeling as the bottleneck that normally restricts HIV-1 infection of resting CD4+ T cells. It shows that cell–cell spread activates CD4–LCK–CDK1 signaling, modifies nucleoporins, and enables capsid nuclear import without requiring entry into the cell cycle.

• Talabostat Mesylate: FAP Assay Workflows

  2026-08-17

  Talabostat mesylate, also known as PT-100, gives researchers a practical pharmacological handle on DPP4 and FAP activity in tumor and immune models. This guide translates that inhibition into cell-based assays, tumor microenvironment studies, cytokine workflows, and mechanistic controls inspired by a pericyte-targeting vascular-disruption study.

• Low-Molecular Weight Inhibitors of the Alternative Pathway

  2026-08-16

  Schubart and colleagues review how factor B and factor D became tractable targets for selective, orally available inhibition of the alternative complement pathway. The article connects pathway biochemistry, medicinal-chemistry challenges, disease genetics, and translational development, providing a framework for interpreting factor B inhibition in complement activation research.

• ECL Chemiluminescent Substrate Detection Kit for AMPK

  2026-08-15

  Use high-sensitivity ECL to resolve low-abundance pathway proteins in microbiome–cancer studies, from UHRF1 and AMPK validation to multiplexed western blot workflows. The enhanced formulation combines low-picogram detection, extended luminescence, and compatibility with film, CCD, and laser imaging for flexible protein immunodetection.

• LDN-193189 for BMP Signaling Workflows

  2026-08-15

  Learn how to deploy LDN-193189 as an ALK inhibitor in phospho-Smad assays, epithelial barrier models, and multipathway cell-culture systems. This workflow-focused guide connects receptor pharmacology with the six-component corneal epithelial culture paradigm while emphasizing solubility, timing, controls, and interpretation limits.

• Dual-Action Inhibitors Promote p38α Dephosphorylation

  2026-08-14

  This preprint shows that selected kinase inhibitors can do more than block p38α catalytic activity: they can also accelerate WIP1-mediated removal of the activation-loop phosphate. Structural and biochemical data indicate that inhibitor-stabilized kinase conformations expose the phospho-threonine, suggesting a route to more effective and selective kinase-directed pharmacology.

• Galectin-1, FIP200, and Hepatic Steatosis

  2026-08-14

  The 2026 reference study identifies a Galectin-1–FIP200 interaction as a mechanistic link between hepatic steatosis, autophagy impairment, and insulin resistance. Its combination of in vivo gain-of-function modeling, proteomic analysis, interaction mapping, and mutation-based validation provides a framework for testing whether altered cellular glucose handling is a downstream functional consequence.

450 records 7/30 page Previous Next First page 上5页 678910 下5页 Last page